Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus complex in HABP/VABP

S/D has the potential to replace polymyxin-based therapy for directed CRAB therapy due to its targeted spectrum of activity and renal safety. Notably, S/D is inappropriate for isolates harboring class B metallo-β-lactamases and/or certain penicillin-binding proteins-3 (PBP3) mutations, those with S/D minimum inhibitory concentration (MIC) ≥4 mcg/mL and in populations with data gaps. Pharmacovigilance, studies of use in broader populations, and cost-effectiveness will be critical to maximize its clinical and stewardship value.